ALZHEIMER'S DISEASE
Clinical trials for ALZHEIMER'S DISEASE explained in plain language.
Never miss a new study
Get alerted when new ALZHEIMER'S DISEASE trials appear
Sign up with your email to follow new studies for ALZHEIMER'S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Alzheimer's drug AL002 safety trial halted early
Disease control TerminatedThis study looked at the long-term safety of an experimental drug called AL002 in 197 people with early Alzheimer's disease. The goal was to see how safe and tolerable the drug was over time, including checking for side effects like brain swelling or bleeding. The study was termi…
Matched conditions: ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated May 26, 2026 02:56 UTC
-
Alzheimer's drug trial halted early: what happened with SPG302?
Disease control TerminatedThis study was designed to see if taking SPG302 daily for a long time is safe and helps slow Alzheimer's in people with mild-to-moderate symptoms. Only 12 people who had already been in an earlier SPG302 study were eligible. The trial was terminated early, so results are limited.
Matched conditions: ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Spinogenix • Aim: Disease control
Last updated May 26, 2026 02:54 UTC
-
Alzheimer's drug trial halted midway: what happened?
Disease control TerminatedThis study tested an experimental drug called SHR-1707 in people with mild memory problems or mild Alzheimer's disease. The goal was to see if the drug could safely reduce harmful protein buildup in the brain. The trial was stopped early, so results are limited.
Matched conditions: ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 02:46 UTC
-
Alzheimer's drug TB006 safety study halted early
Disease control TerminatedThis study looked at the long-term safety of a drug called TB006 in people with Alzheimer's disease. It included people who had already been in a previous TB006 study and new participants. The study was stopped early, and it focused on tracking side effects and how the drug moved…
Matched conditions: ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: TrueBinding, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC